{"result": "(\"entity\"<|>IRENE BRETÓN<|>PERSON<|>Irene Bretón is one of the authors contributing to the topic of obesity treatment in the document.)\n##\n(\"entity\"<|>CYNTHIA GONZÁLEZ-ANTIGÜEDAD<|>PERSON<|>Cynthia González-Antigüedad is one of the authors contributing to the topic of obesity treatment in the document.)\n##\n(\"entity\"<|>MARTA MOTILLA<|>PERSON<|>Marta Motilla is one of the authors contributing to the topic of obesity treatment in the document.)\n##\n(\"entity\"<|>ANA ZUGASTI<|>PERSON<|>Ana Zugasti is one of the authors contributing to the topic of obesity treatment in the document.)\n##\n(\"entity\"<|>PILAR GARCÍA-PERIS<|>PERSON<|>Pilar García-Peris is one of the authors contributing to the topic of obesity treatment in the document.)\n##\n(\"entity\"<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>ORGANIZATION<|>Hospital General Universitario Gregorio Marañón is a hospital in Madrid where the authors are affiliated.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain and the location of the Hospital General Universitario Gregorio Marañón.)\n##\n(\"entity\"<|>OBESIDAD<|>EVENT<|>Obesity is a significant health issue discussed in the document, highlighting its prevalence and associated complications.)\n##\n(\"entity\"<|>CIRUGÍA BARIÁTRICA<|>EVENT<|>Bariatric surgery is a treatment method for obesity discussed in the document, including its evaluation and follow-up.)\n##\n(\"relationship\"<|>IRENE BRETÓN<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Irene Bretón is affiliated with the Hospital General Universitario Gregorio Marañón as an author on obesity treatment<|>8)\n##\n(\"relationship\"<|>CYNTHIA GONZÁLEZ-ANTIGÜEDAD<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Cynthia González-Antigüedad is affiliated with the Hospital General Universitario Gregorio Marañón as an author on obesity treatment<|>8)\n##\n(\"relationship\"<|>MARTA MOTILLA<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Marta Motilla is affiliated with the Hospital General Universitario Gregorio Marañón as an author on obesity treatment<|>8)\n##\n(\"relationship\"<|>ANA ZUGASTI<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Ana Zugasti is affiliated with the Hospital General Universitario Gregorio Marañón as an author on obesity treatment<|>8)\n##\n(\"relationship\"<|>PILAR GARCÍA-PERIS<|>HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN<|>Pilar García-Peris is affiliated with the Hospital General Universitario Gregorio Marañón as an author on obesity treatment<|>8)\n##\n(\"relationship\"<|>OBESIDAD<|>CIRUGÍA BARIÁTRICA<|>Bariatric surgery is a treatment method for obesity discussed in the document<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , Kerr BD, Flatt PR, Gault VA.A novel\n     orlistat (Xenical). Obesity. 2010; 18:108-15.                       GIP-oxyntomodulin hybrid peptide acting through\n33.  Astrup A, Madsbad S, Breum L, Jensen TJ, Krous-                     GIP, glucagon and GLP-1 receptors exhibits weight\n     trup JP, Larsen TM. Effect of tesofensine on bod-                   reducing and anti-diabetic properties. Biochem\n     yweight loss, body composition, and quality of life                 Pharmacol. 2013; 85:1655-62.\n     in obese patients: a randomised, double-blind, pla-           37.   Schmidt JB, Gregersen NT, Pedersen SD, Arentoft\n     cebo-controlled trial. Lancet 2008; 378: 1906-13.                   JL, Ritz C, Schwartz TW, et al. Effects of PYY3-36\n34.  Kim DD, Krishnarajah J, Lillioja S, de Looze F, Marja-              and GLP-1 on energy intake, energy expenditure,\n     son J, Proietto J, et al. Efficacy and safety of beloranib          and appetite in overweight men. Am J Physiol En-\n     for weight loss in obese adults: a randomized con-                  docrinol Metab. 2014; 306:E1248-56.\n     trolled trial.Diabetes Obes Metab. 2015; 17:566-72.           38.   Finan B, Yang B, Ottaway N, Smiley DL, Ma T,\n35.  Irwin N, Flatt PR. Enteroendocrine hormone mime-                    Clemmensen C, et al. A rationally designed mono-\n     tics for the treatment of obesity and diabetes. Curr                meric peptide triagonist corrects obesity and dia-\n     Opin Pharmacol. 2013; 13:989-95.                                    betes in rodents. Nat Med. 2015; 21:27-36.\n---\nNO_CONTENT_HERE\n---\nTema 9.\nObesidad: Tratamiento quirúrgico\nIrene Bretón\nCynthia González-Antigüedad\nMarta Motilla\nAna Zugasti\nPilar García-Peris\nUnidad de Nutrición Clínica y Dietética. Servicio de Endocrinología y Nutrición. Hospital General\nUniversitario Gregorio Marañón. Madrid\n\n\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 143-153.\n\n\n\n   1.  Introducción y epidemiología\n   2.  Cirugía bariátrica: Conceptos generales\n   3.  Cirugía bariátrica: Evaluación preoperatoria y selección de los pacientes\n   4.  Cirugía bariátrica: Seguimiento postoperatorio\n   5.  Complicaciones de la cirugía bariátrica\n   6.  Gestación tras cirugía bariátrica\n   7.  Resumen y conclusiones\n   8.  Bibliografía\n\n\n\n1.   Introducción y epidemiología                                            La importancia de la obesidad está aumentando\n   La obesidad es una de las enfermedades metabólicas                     de un modo alarmante. Incluso en los países en vías de\nmás prevalentes, y se asocia a numerosas complicaciones                   desarrollo constituye un problema emergente, como\nmédicas, psicosociales y a un evidente deterioro en la                    consecuencia de los cambios acelerados en el modo\ncalidad de vida1. La obesidad condiciona un aumento de                    de vida en algunos sectores de la población. Este\nla mortalidad global y da lugar a numerosas enfermeda-                    aumento de la prevalencia es mucho más evidente en\ndes, como son la diabetes mellitus (DM) tipo 2, el síndro-                las formas graves de obesidad, que ha llegado a in-\nme de apnea obstructiva del sueño, enfermedades arti-                     crementarse hasta en un 400 % en los últimos 20\nculares, digestivas, endocrinológicas, neoplasias etc.2.                  años. La obesidad origina unos costes económicos\n   La obesidad es una enfermedad altamente prevalen-                      muy elevados; se estima que en España supone el\n                                                                          6,9 % del gasto sanitario6  .\nte. Los países con prevalencia más elevada de obesi-                         La obesidad se asocia a numerosas complicaciones\ndad, superior al 30 %, son EE UU (aproximadamente el                      médicas y psicosociales. El tratamiento de la obesi-\n34 %), Méjico y Arabia Saudí. En Europa, las tasas más                    dad es complejo y difícil y existe una enorme tenden-\nelevadas corresponden a Reino Unido, Alemania, Bul-                       cia a recuperar el peso perdido. Los mecanismos fi-\ngaria y España.                                                           siológicos que regulan el balance energético\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}